ReviewACS infectious diseases2026
Deadbolt Drug Discovery: Locking the Door to Class 1 Viral Entry by Small Molecules.
Review in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery and Structure-Activity Relationship Studies of Thienopyrroles as Group 2 Influenza A Entry Inhibitors.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The continued emergence of viral pathogens underscores the need for novel antiviral therapeutics with improved efficacy. Small-molecule inhibitors of viral entry are attractive antiviral agents because they block the virus at its earliest step, preventing the virus from entering host cells and causing downstream damage. Some of the viruses of greatest concern for human health, such as human immunodeficiency virus, respiratory syncytial virus, influenza virus, Ebola virus, severe acute respiratory syndrome coronavirus 2, and Lassa virus, encode Class 1 fusion proteins which mediate membrane fusion and viral entry. In this review, we highlight recent advances in the discovery and development of small-molecule entry inhibitors reported over the past five years that target viruses encoding Class 1 fusion proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.